tiprankstipranks
Trending News
More News >
Biosyent Inc (TSE:RX)
:RX
Canadian Market

Biosyent (RX) Income Statement

Compare
51 Followers

Biosyent Income Statement

Last quarter (Q3 2025), Biosyent's total revenue was C$12.22M, an increase of 27.90% from the same quarter last year. In Q3, Biosyent's net income was C$2.68M. See Biosyent’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
C$ 35.03MC$ 31.59MC$ 27.93MC$ 28.62MC$ 22.33M
Gross Profit
C$ 27.86MC$ 25.60MC$ 22.86MC$ 22.64MC$ 17.42M
Operating Expenses
C$ 19.10MC$ 18.13MC$ 15.95MC$ 14.39MC$ 12.30M
Depreciation and Amortization
C$ 589.95KC$ 455.34KC$ 451.00KC$ 457.11KC$ 510.42K
EBITDA
C$ 10.43MC$ 9.06MC$ 7.43MC$ 8.64MC$ 5.54M
Operating Income
C$ 8.75MC$ 7.47MC$ 6.98MC$ 8.18MC$ 5.03M
Other Income/Expenses
C$ 1.03MC$ 1.06MC$ 448.65KC$ 195.22KC$ 206.96K
Pretax Income
C$ 9.78MC$ 8.53MC$ 7.43MC$ 8.38MC$ 5.24M
Net Income
C$ 7.27MC$ 6.46MC$ 5.46MC$ 6.28MC$ 3.80M
Per Share Metrics
Basic EPS
C$ 0.63C$ 0.54C$ 0.44C$ 0.50C$ 0.29
Diluted EPS
C$ 0.62C$ 0.53C$ 0.44C$ 0.49C$ 0.29
Weighted Average Shares Outstanding
11.59M 11.95M 12.30M 12.69M 13.00M
Weighted Average Shares Outstanding (Diluted)
11.81M 12.17M 12.54M 12.87M 13.09M
Currency in CAD

Biosyent Earnings and Revenue History